CL2010001471A1 - Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. - Google Patents

Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..

Info

Publication number
CL2010001471A1
CL2010001471A1 CL2010001471A CL2010001471A CL2010001471A1 CL 2010001471 A1 CL2010001471 A1 CL 2010001471A1 CL 2010001471 A CL2010001471 A CL 2010001471A CL 2010001471 A CL2010001471 A CL 2010001471A CL 2010001471 A1 CL2010001471 A1 CL 2010001471A1
Authority
CL
Chile
Prior art keywords
diseases
treatment
pharmaceutical composition
dibenzo
piperazin
Prior art date
Application number
CL2010001471A
Other languages
English (en)
Spanish (es)
Inventor
Phil Edwards
Dean Brow
James Damenwood
James Hulsizer
Jjames Muir
Jr Edwrds Pierson
Bhikkappa Ashokkumar
Ste Wesolowski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41431860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2010001471A1 publication Critical patent/CL2010001471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL2010001471A 2008-06-20 2010-12-17 Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. CL2010001471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7441708P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
CL2010001471A1 true CL2010001471A1 (es) 2011-05-06

Family

ID=41431860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001471A CL2010001471A1 (es) 2008-06-20 2010-12-17 Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..

Country Status (37)

Country Link
US (3) US20110160184A1 (enExample)
EP (1) EP2307389B1 (enExample)
JP (2) JP5468068B2 (enExample)
KR (1) KR20110019781A (enExample)
CN (1) CN102131791B (enExample)
AR (1) AR072200A1 (enExample)
AU (1) AU2009260905B2 (enExample)
BR (1) BRPI0914231A2 (enExample)
CA (1) CA2728675A1 (enExample)
CL (1) CL2010001471A1 (enExample)
CR (1) CR11860A (enExample)
CU (1) CU23884B1 (enExample)
CY (1) CY1113845T1 (enExample)
DK (1) DK2307389T3 (enExample)
DO (1) DOP2010000393A (enExample)
EA (1) EA201001889A1 (enExample)
EC (1) ECSP10010698A (enExample)
ES (1) ES2402084T3 (enExample)
HN (1) HN2010002683A (enExample)
HR (1) HRP20130234T1 (enExample)
IL (2) IL210081A (enExample)
ME (1) ME01516B (enExample)
MX (1) MX2010014203A (enExample)
MY (1) MY157518A (enExample)
NI (1) NI201000224A (enExample)
NZ (1) NZ590616A (enExample)
PE (1) PE20110029A1 (enExample)
PL (1) PL2307389T3 (enExample)
PT (1) PT2307389E (enExample)
RS (1) RS52703B (enExample)
SI (1) SI2307389T1 (enExample)
SV (1) SV2010003769A (enExample)
TW (1) TWI488854B (enExample)
UA (1) UA105903C2 (enExample)
UY (1) UY31919A (enExample)
WO (1) WO2009154563A1 (enExample)
ZA (1) ZA201100488B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2307389T3 (pl) * 2008-06-20 2013-05-31 Astrazeneca Ab Pochodne dibenzotiazepiny i ich zastosowanie
WO2015021548A1 (en) * 2013-08-12 2015-02-19 Graphite Software Corporation Secure authentication and switching to encrypted domains
CN103524455A (zh) * 2013-10-30 2014-01-22 苏州敬业医药化工有限公司 一种制备2-氯-二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮的方法
EP3072320A4 (en) 2013-11-21 2017-05-24 Graphite Software Corporation Managed domains for remote content and configuration control on mobile information devices
CN104447615A (zh) * 2014-02-28 2015-03-25 广东东阳光药业有限公司 喹硫平中间体的制备方法
CN120981447A (zh) * 2023-03-08 2025-11-18 法兰克福大学 Slack激活化合物及其医学用途
EP4428132A1 (en) * 2023-03-08 2024-09-11 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL294355A (enExample)
NL293201A (enExample)
DE1620703B2 (de) * 1960-08-16 1976-11-25 Ausscheidung aus: 12 80 879 Dr. A. Wander AG, Bern 11-basisch substituierte dibenzo eckige klammer auf b,f eckige klammer zu-eckige klammer auf 1,4 eckige klammer zu-thiazepine
CH422793A (de) 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
DE1620711A1 (de) * 1962-05-25 1970-06-04 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter 5H-Dibenzo[b,e][1,4]diazepine
CH476743A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von Amidinen der Dibenzo (b,e) (1,4)-diazepin-Reihe
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
BE632120A (enExample) 1963-05-09
US3908010A (en) * 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) * 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3683034A (en) * 1963-09-27 1972-08-08 Upjohn Co Process for the preparation of substituted hydroquinones
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
AT278805B (de) * 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
NL6715650A (enExample) 1966-12-16 1968-06-17
US3852446A (en) * 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
JPH04211071A (ja) 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH0565257A (ja) 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
DE69516524T2 (de) 1994-08-24 2001-01-18 Astrazeneca Ab, Soedertaelje Therapeutisch verwendbare spiro-azabicyclische verbindungen
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6703371B1 (en) 1999-07-28 2004-03-09 Oswald Wiss Preparations for reducing oxygen consumption during physical efforts
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
WO2002060870A2 (en) 2000-11-17 2002-08-08 Adolor Corporation Delta agonist analgesics
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
DE60230869D1 (de) 2001-05-18 2009-03-05 Astrazeneca Ab 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
EP1397366B1 (en) 2001-06-01 2007-02-07 AstraZeneca AB Novel ligand for nicotinic acetylcholine receptors useful in therapy
SG152907A1 (en) * 2001-07-09 2009-06-29 Combinatorx Inc Combinations for the treatment of inflammatory disorders
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
KR20090130150A (ko) 2001-09-27 2009-12-17 라모트 앳 텔 아비브 유니버시티 리미티드 접합된 항-정신병 약물 및 그의 용도
ES2348282T3 (es) 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
MXPA04010191A (es) 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos de furilo.
BR0309345A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
CN1681388A (zh) 2002-09-18 2005-10-12 Fmc有限公司 三环衍生物杀虫剂
BR0317528A (pt) 2002-12-20 2005-11-22 Basf Ag Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições
EP1589974A2 (en) * 2003-01-23 2005-11-02 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2004076431A1 (en) 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
CA2527170A1 (en) 2003-04-15 2004-10-28 Astrazeneca Ab Therapeutic compounds
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
PL195728B1 (pl) 2003-07-18 2007-10-31 Helm Ag Sposób wytwarzania 11-(1-piperazynylo)dibenzo[b,f][1,4]tiazepiny
RU2394030C2 (ru) * 2003-12-22 2010-07-10 Акадиа Фармасьютикалз Инк. АМИНОЗАМЕЩЕННЫЕ АНАЛОГИ ДИАРИЛ [a,d] ЦИКЛОГЕПТЕНА В КАЧЕСТВЕ МУСКАРИНОВЫХ АГОНИСТОВ И СПОСОБЫ ЛЕЧЕНИЯ ПСИХОНЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
PL1696931T3 (pl) 2003-12-22 2009-10-30 Acadia Pharm Inc Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
BRPI0517423A (pt) 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP2099459A4 (en) 2006-12-20 2011-04-27 Astrazeneca Ab COMPOUNDS AND USES THEREOF
WO2008100715A1 (en) 2007-02-09 2008-08-21 Astrazeneca Ab Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
US7491871B2 (en) 2007-04-25 2009-02-17 Stine Seed Farm, Inc. Soybean cultivar S060299
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
PL2307389T3 (pl) * 2008-06-20 2013-05-31 Astrazeneca Ab Pochodne dibenzotiazepiny i ich zastosowanie

Also Published As

Publication number Publication date
CY1113845T1 (el) 2016-07-27
AU2009260905A1 (en) 2009-12-23
NI201000224A (es) 2012-03-19
CN102131791B (zh) 2014-12-24
CU20100252A7 (es) 2011-11-15
PL2307389T3 (pl) 2013-05-31
US20090318415A1 (en) 2009-12-24
CA2728675A1 (en) 2009-12-23
ECSP10010698A (es) 2011-01-31
RS52703B (sr) 2013-08-30
IL210081A0 (en) 2011-02-28
EP2307389B1 (en) 2013-01-23
JP2011524898A (ja) 2011-09-08
CN102131791A (zh) 2011-07-20
EP2307389A4 (en) 2012-04-11
NZ590616A (en) 2012-09-28
PE20110029A1 (es) 2011-02-11
DK2307389T3 (da) 2013-04-02
EP2307389A1 (en) 2011-04-13
ES2402084T3 (es) 2013-04-26
MY157518A (en) 2016-06-15
BRPI0914231A2 (pt) 2015-11-03
SV2010003769A (es) 2011-05-20
US8653257B2 (en) 2014-02-18
HK1156308A1 (en) 2012-06-08
UA105903C2 (uk) 2014-07-10
US20120202991A1 (en) 2012-08-09
DOP2010000393A (es) 2011-01-31
AR072200A1 (es) 2010-08-11
HN2010002683A (es) 2013-01-15
EA201001889A1 (ru) 2011-08-30
IL229560A0 (en) 2014-01-30
JP5468068B2 (ja) 2014-04-09
SI2307389T1 (sl) 2013-04-30
CU23884B1 (es) 2013-04-19
US8158618B2 (en) 2012-04-17
KR20110019781A (ko) 2011-02-28
JP2014098006A (ja) 2014-05-29
UY31919A (es) 2010-01-29
ME01516B (me) 2014-04-20
WO2009154563A1 (en) 2009-12-23
CR11860A (es) 2011-02-25
ZA201100488B (en) 2011-10-26
PT2307389E (pt) 2013-03-28
MX2010014203A (es) 2011-02-22
US20110160184A1 (en) 2011-06-30
TW201002702A (en) 2010-01-16
TWI488854B (zh) 2015-06-21
IL210081A (en) 2013-12-31
AU2009260905B2 (en) 2012-08-23
IL229560A (en) 2015-07-30
HRP20130234T1 (hr) 2013-04-30

Similar Documents

Publication Publication Date Title
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2010001471A1 (es) Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades..
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2009000447A1 (es) Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
AR047529A1 (es) Compuestos de quinolina sustituidos
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
UY30121A1 (es) Nuevos compuestos